8-K
filed February 2, 2024, 6:59 PM ET
ticker BMY
CIK 0000014272
earnings
confidence high
sentiment neutral
materiality 0.80
Bristol Myers Q4 rev up 1% to $11.5B; Non-GAAP EPS $1.70; FY rev $45.0B; 2024 EPS guide $7.10-$7.40
BRISTOL MYERS SQUIBB CO
2023-FY EPS reported
$3.86
revenue$45,006,000,000
- Fourth quarter revenues $11.5B (+1% YoY); GAAP EPS $0.87, Non-GAAP EPS $1.70.
- Full-year revenues $45.0B (-2% YoY); GAAP EPS $3.86, Non-GAAP EPS $7.51.
- In-line & new product portfolio revenues: +9% in Q4, +7% in FY to $37.9B.
- 2024 guidance: revenue growth low single-digits; Non-GAAP EPS $7.10-$7.40 (excl. pending acquisitions).
- Pipeline: FDA approval of Augtyro; Breyanzi sBLAs accepted; completed Mirati purchase, pending Karuna & RayzeBio.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
BRISTOL MYERS SQUIBB CO reported the fourth quarter of 2023 results: revenue $11,477, EPS GAAP EPS of $0.87 and Non-GAAP EPS of $1.70.
- Period
- the fourth quarter of 2023
- Revenue
- $11,477
- EPS
- GAAP EPS of $0.87 and Non-GAAP EPS of $1.70
- Result
- reported results
Exact text from the filing
the decade and beyond." 1 Fourth Quarter Full Year $ in millions, except per share amounts 2023 2022 Change Change Excl. F/X** 2023 2022 Change Change Excl. F/X** Total Revenues $11,477 $11,406 1 % 1 % $45,006 $46,159 (2) % (2) % EPS — GAAP* 0.87 0.95 (8) % N/A 3.86 2.95 31 % N/A EPS — Non-GAAP* 1.70 1.82 (7) % N/A 7.51 7.70 (2) % N/A Acquired IPRD charge and
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
BRISTOL MYERS SQUIBB CO reported full year of 2023 results: revenue $45,006, EPS GAAP EPS of $3.86 and Non-GAAP EPS of $7.51. Guidance initiated.
- Period
- full year of 2023
- Revenue
- $45,006
- EPS
- GAAP EPS of $3.86 and Non-GAAP EPS of $7.51
- Guidance
- initiated
- Result
- reported results
Exact text from the filing
1 Fourth Quarter Full Year $ in millions, except per share amounts 2023 2022 Change Change Excl. F/X** 2023 2022 Change Change Excl. F/X** Total Revenues $11,477 $11,406 1 % 1 % $45,006 $46,159 (2) % (2) % EPS — GAAP* 0.87 0.95 (8) % N/A 3.86 2.95 31 % N/A EPS — Non-GAAP* 1.70 1.82 (7) % N/A 7.51 7.70 (2) % N/A Acquired IPRD charge and Licensing Income Net Impact
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.